Canary Global Inc.

British Airways | BRITISH AIRWAYS TRIALS ‘WORLD FIRST’ 25 SECOND COVID-19 TEST mediacentre.britishairways.com/pressrelease/d…

BA.2.75.2 may be “a” concern, but it’s not “the” concern. What is worrying is the trend that happened in the last few months in Omicron, and more robust in the polytomy of BA.2.75 - The RBD region, which was highly conserved in the past, shows increasing plasticity. 1/4

Promises made… promises need to be kept, @JoeBiden. Thank you.

Looking forward to hosting Dr Lisa Newman @BrighamSurgery and @DFCI_BreastOnc for Carolyn Kaelin visiting Professorship.

Our chief fellow @Sunil_G_Iyer presenting important collaborative effort between @SylvesterCancer and @MSKCancerCenter to improve HCT utilization in racial minorities at the 15th. @AACR Conference on Cancer Care Disparities. #AACRdisp22 #bmtsm

World… meet Mozzarella and her balsamic ears @darth

Published today: @TheLancet Commission on Covid-19: "a massive global failures" with recommendations going forward thelancet.com/commissions/co… It's a 57-page paper. I think this Figure and the 1-pager editorial summarize it well

Will you pray for home less pets ? 🙏 Like = Yes ✅️ Ignore = No ❌️

With #ESMO22 turning to history, on the plane back to 🇬🇷, Ι added a column of main outcomes/potential clinical relevance in my previous list of influential trials in #NSCLC 🙏@myESMO staff, officers,speakers,chairs, attendees for a magical experience! @OncoAlert #some #LCSM

Day 4 #ESMO22 Highlights from #CommunityOncologists perspective: 1. #IFCT1701 - ICI in mNSCLC 2. #POSEIDON Update - mNSCLC @MLJohnsonMD2 3. #CodeBreak200 - KRAS G12C NSCLC @MLJohnsonMD2 #LCSM #MedTwitter #OncEd @HemOncFellows @OncoAlert @myESMO 1/9

Probably the most awaited trial #ESMO22. CODEBREAK200 (sotorasib vs doc in 2/3L NSCLC) ✅PFS HR 0.66 (5.6 vs 4.5 m / 24.8 vs 10.1% at 1 yr) ✅ORR 28.1 vs 10.2 % ❎OS HR 1.01 ✅fewer gr. ≥3 & serious TRAEs  Endless discussion regarding the magnitude of benefit awaited @OncoAlert

Nivo IPI adjuvant RCC is negative. Larger than life @motzermd presenting! Standing room only. Is it tolerability that caused this? 57% completed all cycles. Sizeable pT2 group and no M1NED may have made the population less high risk. @OncoAlert @IMDConline @bmsnews

A patient presents with a distended abdomen. His eyes look like this. What’s the diagnosis? #MedTwitter

Don't be numb to this wsj.com/articles/covid… by @jon_kamp

Congratulations to⁩ ⁦⁦@CharlesSwanton⁩ for an elegant answer to the question of LC causality in never smokers! Opening the possibility of LC prevention with IL 1b inh. Similarly to tobacco exposure, we should reduce PM2.5 air pollution exposure. ⁦@myESMO⁩

#Lungcancer awareness month is November! Join us this #LCAM and show your support by either making or buying a white ribbon! Check out here for more white ribbon resources: bit.ly/3QpfvyD

Updated @NCCN guidelines recommends genetic testing in all women <50 yrs at breast ca dx.Our study in @JCO_ASCO ⬇️ has shown that this threshold will miss >10% of BRCA1/2 carriers.We need to expand testing to all women under 65 at breast ca dx to identify >95% of BRCA1/2 carriers

Dose matters !!! DESTINY-LUNG02 trial. Same efficacy, less toxicity including pneumonitis in HER2 mut #NSCLC with 5.4 vs 6.4 dose. Should be the standard dose. Please include patient in DESTINY-LUNG04 trial (exp arm dose is 5.4) #ESMO22 @OncoAlert

This is a coffee shop in Greece 🇬🇷 , which opens its door to stray dogs every night so they don freeze to death 😍😍

It wasn't an easy journey but I couldn't be more grateful. A million thanks to all the friends and family who made it possible! and to @USJLiban @UWorldMedical @ambossmed Excited for what the future holds! @StoriesImg @IMG_Advocate @ImgJourney